Programming Cell Therapies to Overcome Solid Tumor Defense Systems - a podcast by The Bio Report
from 2021-09-16T08:00:26
::
::
While CAR-T cell therapies have emerged as promising anti-cancer agents, their success have been focused on hematologic cancers. ArsenalBio is working to develop more robust cell therapies capable to treating a broader range of cancers by using synthetic biology to make them programable. We spoke to Ken Drazen, CEO of ArsenalBio, about the company’s next-generation T cell therapies, how it is able to program functions into these cells to overcome solid tumor defenses, and the company’s collaboration with Bristol-Myers Squibb announced at the start of the year.
Further episodes of The Bio Report
Further podcasts by The Bio Report
Website of The Bio Report